1.25
price down icon1.57%   -0.02
after-market After Hours: 1.24 -0.01 -0.80%
loading
Sonnet Biotherapeutics Holdings Inc stock is traded at $1.25, with a volume of 206.77K. It is down -1.57% in the last 24 hours and down -13.79% over the past month. Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
See More
Previous Close:
$1.27
Open:
$1.7
24h Volume:
206.77K
Relative Volume:
1.55
Market Cap:
$3.83M
Revenue:
$129.20K
Net Income/Loss:
$-7.44M
P/E Ratio:
-0.1117
EPS:
-11.19
Net Cash Flow:
$-8.62M
1W Performance:
-4.58%
1M Performance:
-13.79%
6M Performance:
-75.73%
1Y Performance:
-92.11%
1-Day Range:
Value
$1.25
$1.70
1-Week Range:
Value
$1.22
$1.70
52-Week Range:
Value
$1.22
$16.80

Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile

Name
Name
Sonnet Biotherapeutics Holdings Inc
Name
Phone
609-375-2227
Name
Address
100 OVERLOOK CENTER, PRINCETON, NJ
Name
Employee
13
Name
Twitter
@SonnetBio
Name
Next Earnings Date
2024-08-12
Name
Latest SEC Filings
Name
SONN's Discussions on Twitter

Compare SONN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SONN
Sonnet Biotherapeutics Holdings Inc
1.25 3.83M 129.20K -7.44M -8.62M -11.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Sonnet Biotherapeutics Holdings Inc Stock (SONN) Latest News

pulisher
12:57 PM

Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up - MarketScreener

12:57 PM
pulisher
09:31 AM

Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo - TipRanks

09:31 AM
pulisher
09:18 AM

Sonnet BioTherapeutics advances in cancer trial - Investing.com

09:18 AM
pulisher
09:03 AM

Sonnet'S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer - MarketScreener

09:03 AM
pulisher
09:01 AM

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - GlobeNewswire

09:01 AM
pulisher
Apr 01, 2025

Sonnet Announces Release of Corporate Update Video - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO and new president By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO and new president - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Pilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech Company - dailyvoice.com

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - citybiz

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO after founder’s death - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Leadership Change at Sonnet BioTherapeutics: Founder Passes, New Executive Team Steps In - Stock Titan

Apr 01, 2025
pulisher
Mar 30, 2025

Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter

Mar 29, 2025
pulisher
Mar 28, 2025

SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia

Mar 28, 2025
pulisher
Mar 27, 2025

Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire

Mar 27, 2025
pulisher
Mar 26, 2025

Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Clinical Trial Success: New Cancer Drug Combo Shows 83% Disease Control in Sarcoma Patients - Stock Titan

Mar 26, 2025
pulisher
Mar 21, 2025

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 16.4% in February - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics Receives Notice of Allowance for - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Major Patent Win: Sonnet's Revolutionary IL-18 Cancer Treatment Shows Superior Binding Properties - StockTitan

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein - The Manila Times

Mar 19, 2025
pulisher
Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 - StockTitan

Mar 11, 2025
pulisher
Mar 11, 2025

XRP Plunges as Recession Panic and Crypto Summit Fallout Slam Investors - The Globe and Mail

Mar 11, 2025
pulisher
Mar 07, 2025

Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga

Mar 07, 2025
pulisher
Mar 04, 2025

SONN stock touches 52-week low at $1.33 amid market challenges - Investing.com UK

Mar 04, 2025
pulisher
Feb 27, 2025

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Highlights Promising SON-1010 Data - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Presents Innovative FHAB® Platform Data at 2025 AACR:IO Conference - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Presents Compilation of Data - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Can This Immunotherapy Beat Solid Tumors? Sonnet's SON-1010 Shows 48% Clinical Benefit - StockTitan

Feb 26, 2025
pulisher
Feb 21, 2025

Sonnet BioTherapeutics Announces Availability of Proprietary ADC Platform for Drug Discovery Partnerships - The AM Reporter

Feb 21, 2025
pulisher
Feb 20, 2025

Sonnet BioTherapeutics advances novel ADC platform By Investing.com - Investing.com Australia

Feb 20, 2025
pulisher
Feb 19, 2025

Sonnet BioTherapeutics advances novel ADC platform - Investing.com

Feb 19, 2025
pulisher
Feb 19, 2025

SONN stock touches 52-week low at $1.38 amid market challenges - Investing.com India

Feb 19, 2025
pulisher
Feb 19, 2025

Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Sonnet BioTherapeutics Announces That Its Proprietary - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform - TipRanks

Feb 19, 2025
pulisher
Feb 19, 2025

2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street - The Globe and Mail

Feb 19, 2025
pulisher
Feb 19, 2025

Can This New ADC Platform Challenge Established Cancer Drugs? Preclinical Data Shows Promise - StockTitan

Feb 19, 2025

Sonnet Biotherapeutics Holdings Inc Stock (SONN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):